19F |
Fluorine-19 |
ATMP |
advanced therapy medicinal product |
BMI |
body-mass index |
CXCL12 |
C-X-C Motif Chemokine Ligand 12 |
D2R |
dopamine 2 receptors |
DOA |
detrusor overactivity |
DTI |
diffusion tensor imaging |
EUS |
external urethral sphincter |
FDA |
Food and Drug Administration |
GCP |
good clinical practice |
GMP |
good manufacturing practice |
ICIQ |
International Consultation on Incontinence Questionnaire |
ICIQ-SF |
International Consultation on Incontinence Questionnaire–Short Form |
ICS |
International Continence Society |
ISD |
intrinsic sphincter deficiency |
LPP |
leak point pressure |
MDSC |
muscle-derived stem cell |
MPC |
muscle progenitor cell |
MRI |
magnetic resonance imaging |
MSC |
mesenchymal stromal cell |
MT |
magnetization transfer |
MUCP |
maximal urethral closure pressure |
NMES |
neuromuscular electromagnetic stimulation |
pADSC |
porcine adipose tissue-derived stromal cell |
PET |
positron emission tomography |
PRO |
patient reported outcome |
QoL |
quality of life |
SPIO |
superparamagnetic iron oxide |
SSNRI |
selective serotonin noradrenaline inhibitors |
SUI |
stress urinary incontinence |
TE |
tissue engineering |
TVT |
tension free vaginal tape |
UI |
urinary incontinence |
VLPP |
Valsalva leak point pressure |
µCT |
micro-computed tomography |